Compare ALAR & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | APRE |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 11.5M |
| IPO Year | 2018 | 2019 |
| Metric | ALAR | APRE |
|---|---|---|
| Price | $1.87 | $0.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $14.00 | $4.10 |
| AVG Volume (30 Days) | ★ 146.7K | 53.9K |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.51 | N/A |
| Revenue Next Year | $33.43 | N/A |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $0.55 |
| 52 Week High | $18.00 | $1.79 |
| Indicator | ALAR | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 45.64 |
| Support Level | $1.62 | $0.58 |
| Resistance Level | $7.54 | $0.83 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 53.06 | 54.70 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.